Xeltis shortlisted for Company of the Year
Xeltis has been shortlisted for the BioCapital Europe Company of the Year award. Xeltis is one of five companies to be potentially awarded the Prize by delegates during the BioCapital Europe event today.
The award will be based on the company’s presentation at the meeting. For the second consecutive year, CEO Laurent Grandidier will present Xeltis’ significant advancement in 2016.
“Xeltis has progressed at a remarkable pace over the past year to the point where our heart valves are now functioning in 12 young hearts through our clinical trials. We are honored to be nominated and recognized for our progress by life science industry institutions,” summarized Laurent Grandidier.
Taking place in Amsterdam, BioCapital Europe is a leading life sciences investment conference. It offers potential investors access to around 40 European biotech companies. The invitation-only event is now in its 15th year.